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Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are the two major causative agents of hand, foot
and mouth disease (HFMD), for which there are currently no licenced treatments. Here, the acquisition of
resistance towards two novel capsid-binding compounds, NLD and ALD, was studied and compared to
the analogous compound GPP3. During serial passage, EV71 rapidly became resistant to each compound
and mutations at residues I113 and V123 in VP1 were identified. A mutation at residue 113 was also
identified in CVA16 after passage with GPP3. The mutations were associated with reduced thermosta-
bility and were rapidly lost in the absence of inhibitors. In silico modelling suggested that the mutations
prevented the compounds from binding the VP1 pocket in the capsid. Although both viruses developed
resistance to these potent pocket-binding compounds, the acquired mutations were associated with
large fitness costs and reverted to WT phenotype and sequence rapidly in the absence of inhibitors. The
most effective inhibitor, NLD, had a very large selectivity index, showing interesting pharmacological
properties as a novel anti-EV71 agent.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Hand, foot and mouth disease (HFMD) usually manifests as a
mild self-limiting childhood infection, causing sores on the hands,
feet, mouth and buttocks, but can be associated with more serious
symptoms, including fatal neurological/cardiovascular disorders.
HFMD is usually caused by Enterovirus A species picornaviruses,
especially enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16),
with EV71 more commonly associated with severe disease
(Mcminn, 2003). EV71-mediated HFMD is therefore the major
picornavirus-related public health problem in a post-poliovirus era
and there are currently no clinically-approved therapeutic or pro-
phylactic treatments.
WIN compounds and related molecules prevent receptormal inhibitory concentration;
issue culture infectious dose.




r B.V. This is an open access articleattachment/uncoating of a number of enteroviruses (Pevear et al.,
1999). These compounds bind to a cavity in the capsid (the
pocket in one of the viral capsid proteins, VP1) displacing hydro-
phobic lipids termed pocket factors. These are expelled upon re-
ceptor binding or uncoating, allowing the capsid to undergo a
conformational change resulting in release of the RNA genome
(Dang et al., 2014; Ren et al., 2013; Wang et al., 2012). The relatively
high affinity between the pocket andWIN compounds prevents the
conformational changes necessary for uncoating, increasing capsid
stability (Rotbart et al., 1998) and can be effective at preventing
infection in culture (Pevear et al., 1999; Shia et al., 2002; Benschop
et al., 2015), and murine models (Groarke and Pevear, 1999; Liu
et al., 2012). One compound, Vapendavir (BTA798), has shown ef-
ficacy in asthmatic patients with human rhinovirus (HRV) in-
fections in phase II trials (Feil et al., 2012).
A related compound, Pleconaril, was used as a model to design a
new class of pyridyl imidazolidinones, (IC50 values against EV71 of
0.001e25 mM), the most potent of which was termed GPP3 (Ke and
Lin, 2006; Shia et al., 2002). Crystallographic analysis of EV71
(Plevka et al., 2012; Wang et al., 2012) in complex with four
different pyridyl imidazolidinones, combined with computationalunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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were used to develop two new compounds (NLD and ALD), based
upon GPP3 (De Colibus et al., 2014). NLD was shown to have more
than an order of magnitude greater potency against EV71 than
GPP3, IC50 ¼ 25 pM. GPP3 and the new derivative compounds also
had anti-CVA16 activity.
To identify mutations associated with resistance, EV71/CVA16
were passaged eight times in the presence of these compounds at
concentrations that reduced the TCID50 values by over 99.9% (see
supplementary information). Virus titres in the presence of the
compounds rapidly rose to WT-equivalent levels (~1  107 TCID50/
ml for EV71 and ~1  105 TCID50/ml for CVA16), indicating the
acquisition of resistance (Fig. 1). Sequencing revealed three
different VP1 mutants in EV71 (I113L, I113M, I113M/V123I) and one
in CVA16 (L113F) (Table 1). Virus passaged in a combination of NLD/
GPP3 over 30 passages maintained the I113M/V123I mutations
(n ¼ 1).
The crystal structure of EV71 in complex with NLD enabled
visualisation of the NLD binding site within the protomeric unit of
the capsid, this showed that all interactions of NLD are with VP1
(Fig. 2A) (De Colibus et al., 2014). Fig. 2B and C shows the in-
teractions close-up, with key stabilising interactions highlightedFig. 1. Generation of resistant isolates. WT EV71 was passaged in the presence of either (A)
0.9 nM GPP3, (E) WT CVA16 was passaged in the presence of 20 nM GPP3. Each isolate was pa
the selecting concentration of compound. CVA16 isolates resistant to NLD or ALD were notand the location of the resistance mutations in EV71, respectively.
Mutations I113M and V123I are located on the inside of the VP1
pocket and I113 is one of the residues involved in compound
binding (Fig. 2B). Fig. 2D shows the location of the resistance mu-
tation for CVA16 in the context of the adjacent GPP3 molecule.
Studies with other enteroviruses have documented many mu-
tations associated with resistance to a variety of pocket-binding
compounds (see Supplementary Information). Generally, resistant
viruses have acquired mutations that interfere with the correct
placement of the inhibitors in the binding pocket (Liu et al., 2012).
To test this in the EV71/CVA16 resistant-isolates, in silico folding
energy predictions resulting from the mutations were performed
using Rosetta (Fowler et al., 2010; Kellogg et al., 2011; Tyka et al.,
2011) on VP1 subunits. The difference in the lowest free energy of
folding (DDGfolding) between the WT and EV71 I113M or V123I
mutants was þ0.73 and þ 0.98 kcal/mol, respectively. The combi-
nation of both mutations gave DDGfolding of ~þ1.1 kcal/mol per VP1
(note that this value should be multiplied by 60 to reflect the
number of VP1 molecules per capsid), suggesting that the mutant
virus capsid is less stable than WT. The mutations I113M and V123I
appeared to cause a shrinking of the VP1 pocket, with the methi-
onine residue pointing inside, suggesting a steric clash with the0.1 nM NLD, (B) 0.9 nM GPP3, (C) 80 nM ALD or, (D) a combination of 0.1 nM NLD and
ssaged a total of 8 times and after each passage a sample was titrated in the presence of
selected.
Table 1
Resistance mutations. Mutations identified in EV71/CVA16 after passage in the presence of NLD, GPP3, ALD or a combination of NLD/GPP3 (see
Fig. 1). CVA16 isolates resistant to NLD or ALD were not selected.
Virus/Compound Mutation(s) Number sequenced
EV71/NLD I113M (62%), I113L (31%), I113M/V123I (7%) n ¼ 13
EV71/GPP3 I113M/V123I n ¼ 4
EV71/ALD I113M/V123I n ¼ 1
EV71/NLD þ GPP3 I113M/V123I n ¼ 12
CVA16/GPP3 L113F n ¼ 10
Fig. 2. (A) Structure of EV71 protomer in complex with NLD. Icosahedral protomeric unit of EV71 (PDBid:4CEY), viewed from the inside of the capsid. VP1, blue, VP2, green, VP3 red,
VP4 yellow, NLD magenta. Protein shown in cartoon representation, NLD as spheres, with the chemical structures of GPP3, NLD and ALD molecules reported below. (B) Structure of
EV71 pocket in complex with NLD. EV71 (PDBid 4CEY) showing a close-up of the VP1 (blue) pocket with NLD (magenta) in-place. The side-chains of F135, F155, D112 and I113 and
NLD are shown as ball-and-sticks. Hydrogen bonds are shown as dashed (C) Predicted structure of inhibitor resistant mutant in complex with NLD. EV71 (PDBid 4CEY) in blue, with
VP1 model generated by Rossetta shown in grey. The two mutated side chains I113M and V123I are shown as grey balls-and-sticks. The distance between the M113 side chain and
NLD linker, corresponding to 2.1 Å, is shown as a dotted line. (D) Structure of CVA16 (PDBid:5ABJ) in complex with GPP3. Close-up view of the VP1 pocket (in blue) with GPP3 bound
(magenta). The side chains of Y135 and F155 are shown as blue ball-and-sticks. The predicted structure of the inhibitor-resistant mutant in complex with GPP3 is shown in grey with
the L113F mutation in grey ball-and-sticks. In all ball-and-stick representation, nitrogen atoms are blue, oxygen red and sulphur yellow. Sequencing shows a change to M or F could
be achieved by a single point mutation for both EV71 and CVA16. Comparison with the NCBI gene bank database revealed that none of the 5830 EV71 or 248 CVA16 sequences
deposited contained any combination of these mutations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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methyl group of the methionine side chain and a carbon atom in
the linker of NLD is 2.1 Å (Fig. 2C), smaller than the sum of the Van
der Waals radii and leading to a repulsive interaction. However, the
DDGfolding for the CVA16mutant was1.7 kcal/mol, suggesting that
the mutant is more stable than WT (not taking pocket factor into
account). The Rosetta structures are shown in grey in Fig. 2C and D.
It has been reported that pocket-binding compounds increased
thermostability of WT PV and HRVs, while inhibitor-resistant iso-
lates with mutations in the pocket were often more thermolabilethan their untreated WT counterpart (Katpally et al., 2007; Mosser
et al., 1994; Shepard et al., 1993). The thermostabilities of WT EV71
and inhibitor-resistant mutant virus selected in the presence of
NLD/GPP3 were therefore evaluated. WT EV71 (heated with NLD)
was tolerant of temperatures ~6 C higher before detectable inac-
tivation and 2.5 C higher before complete inactivation occurred,
compared to virus in the absence of NLD (Fig. 3A). In contrast, the
thermostability of inhibitor-resistant virus was not increased in the
presence of NLD or by a combination of GPP3 and NLD. In addition,
the inhibitor-resistant mutant virus was more thermolabile than
Fig. 3. Inhibitor-resistant mutants are more thermolabile than WT virus. (A) Ther-
molability curves of EV71 WT (filled circle) and inhibitor-resistant EV71 (open square),
WT EV71 in the presence of 2 nM NLD (open circle), inhibitor-resistant EV71 in the
presence of 0.9 nM GPP3 and 0.1 nM NLD (open triangle) and 2 nM NLD (filled triangle)
(B) Thermolability curves of WT CVA16 (filled circle) and inhibitor-resistant CVA16
(open square). All samples were heated at a range of temperatures for 30 min using a
thermocycler, prior to titration by TCID50 assay. Samples containing NLD were first
diluted to a level at which the inhibitor has no effect before titration. Titrations were
carried out in triplicate and error was measured using standard deviation.
Fig. 4. One step growth curves comparing inhibitor-resistant and WT EV71. WT (filled
circle) and inhibitor-resistant EV71 selected in the presence of 0.1 nM NLD and 0.9 nM
GPP3 (open square) were used to infect six wells each of a 96 well plate at an MOI of
10. Every 3 h the supernatant and cells of a well from each isolate were removed, and
freeze-thawed to lyse the cells. These samples were then titrated by TCID50 assay.
Fig. 5. Inhibitor-resistant isolates are genetically unstable. A NLD/GPP3 inhibitor-
resistant isolate selected with a combination of 0.1 nM NLD and 0.9 nM GPP3 was
passaged four times in the absence of inhibitor. Virus from each passage was titrated in
the presence (filled circles) or absence of inhibitors (open squares) by TCID50 assay.
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lower. Similar results were obtained with inhibitor-resistant CVA16
(Fig. 3B).
These data suggest that the I113M/V123I mutation prevented
compound binding as the thermostability of the resistant isolates
was not increased in the presence of NLD. The bulkier side chains of
the I113M and L113F mutations are predicted to point directly into
the pocket, reducing the space available for inhibitor binding and
the V123I mutation reduces this further. The DDGfolding calculations
predicted that there is a difference in the stability of viruses car-
rying the resistance mutations (in the absence of pocket factor),
however, it is likely that themutations also have a deleterious effect
on the binding of the natural pocket factor, which is known to be a
virion stabiliser. Similar results have been reported for WIN51711-
resistant PV3 and WIN52035-2-resistant HRV14, with mutations
identified in the VP1 pocket (Mosser et al., 1994; Shepard et al.,
1993).
To assess whether the mutations affected growth kinetics, one-
step growth curves were performed with WT EV71 and a resistant
isolate. These showed no significant difference between the WT
and the resistant virus (Fig. 4). The phenotype of themutant viruses
described here is consistent with previous observations with other
picornaviruses (Groarke and Pevear, 1999; Heinz et al., 1989;
Lacroix et al., 2014; Liu et al., 2012; Mosser et al., 1994; Salvati
et al., 2004). However, it should be noted that a small difference
in kinetics of virus resistant to BPR0Z-19 has been reported (Shih
et al., 2004).
Mutations are often associated with a fitness cost, therefore the
genetic stability of inhibitor-resistant EV71 was tested by passagein the absence of inhibitors. The titre in the presence of inhibitor
dropped dramatically after just one passage. After two further
passages the titre became equivalent to the WT in the presence of
the inhibitors (Fig. 5). Sequencing confirmed that the virus had
reverted to a WT genotype (n ¼ 1), indicating a strong selection
pressure for reversion. However, it should be noted that as this
experiment was performed with a pool of viruses, it is not formally
possible to distinguish between the amplification of residual WT
virus in the population and back-mutation of selectedmutant virus.
Fitness costs appear to be common in pocket inhibitor-resistant
enteroviruses, with Pleconaril-resistant CVB3 and V-073-resistant
PV causing reduced virulence in murine models (Groarke and
Pevear, 1999; Kouiavskaia et al., 2011). Similarly, Pleconaril-
resistant HRV B isolated from patients was shown to be non-
pathogenic and was associated with a greatly reduced viral load
(Pevear et al., 2005). The avirulent PV Sabin strains are also ther-
molabile and other thermolabile EV71mutants have been shown to
have reduced pathogenesis in Cynomolgus monkeys (Arita et al.,
2005). Given the apparent fitness cost of these mutations, resis-
tance may not pose an obstacle to the therapeutic use of pocket-
binding compounds. Indeed, assessment of the toxicity of the
three compounds showed NLD to have a large selectivity index
(Fig. 6, Table 2). However, further work will be necessary in order to
evaluate if inhibitor-resistant EV71/CVA16 mutants are less
virulent.
In conclusion, we have described the selection and characteri-
sation of resistance mutations of EV71 in the presence of three
pocket-binding inhibitory compounds. We modelled these
Fig. 6. Toxicity of NLD, GPP3 and ALD to Vero cells. Vero cells were incubated with a
range of concentrations of NLD (closed inverted triangle), GPP3 (filled square), ALD
(filled circle) (A) or DMSO (B) for seven days. MTT assays were then performed and the
CC50 was derived from the OD (692 nm) by non-linear regression. Each point repre-
sents an average of three independent experiments and standard deviation values are
shown. The CC50 values for the three inhibitors were 1.6 mM, 1.0 mM and 7.0 mM
respectively. DMSO (1%) had no apparent cytotoxic effect.
Table 2
Selectivity index. The selectivity index of each compound was calculated by dividing
the CC50 by the IC50 value. IC50 values are for strain EV71 Genotype B2, Strain
MS742387, taken from De Colibus et al. (2014), which was grown in Vero cells.
NLD GPP3 ALD
CC50 (Cell toxicity) 1600 nM 1000 nM 7000 nM
IC50 (Virus inhibition) 0.025 nM 0.39 nM 8.7 nM
Selectivity Index (CC50: IC50) 6  104 2.6  103 8  102
J.T. Kelly et al. / Antiviral Research 124 (2015) 77e82 81mutations in the VP1 pocket to explain their effect on the binding
mode of the pocket factor and calculated the DDGfolding of these
mutants. The in silico predictions were in agreement with some of
the observed properties of the viruses in vitro. Furthermore we
found that the most effective EV71 pocket-binding inhibitor, NLD,
has the greatest selectivity index, showing interesting pharmaco-
logical properties as a novel anti-EV71 agent.
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